Belite Bio, Inc. ADR BLTE 深 沪
等待开盘 06-26 09:30:00 美东时间
150.00
-0.770
-0.51%
华盛通- 最 高152.70
- 今 开151.00
- 成交量 26.18万股
- 最 低 144.51
- 昨 收 150.77
- 总市值 373.01万
- 52周最高 200.00
- 市盈率 静 --
- 换手率 1052.98%
- 52周最低 57.99
- 委 比 79.37%
- 总股本 2.49万
- 历史最高 200.00
- 量 比 1.07
- 振 幅 5.43%
- 历史最低 1.10
- 每 手 1
- 风险率 43.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is unchanged from the same period last year.
05-20 18:09
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
Exploring Belite Bio's Earnings Expectations
Belite Bio (NASDAQ:BLTE) is set to give its latest quarterly earnings report on...
02-28 00:00
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Earnings Outlook For Belite Bio
Belite Bio (NASDAQ:BLTE) is set to give its latest quarterly earnings report on...
2025-11-07 23:02
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
BioAtla's Ozuriftamab Vedotin (Oz-V) shows 45% ORR and 100% DCR in HPV+ OPSCC patients with 3 prior therapies. Current treatments have 3.4% ORR. BioAtla plans Phase 3 trial discussions with FDA for 2L+ HPV+ OPSCC.
2025-06-02 12:00
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $60 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $60 price target.
2024-09-12 18:47
Reported Earlier, Belite Bio Taps Hendrik P. N. Scholl of Institute of Molecular and Clinical Ophthalmology Basel (IOB) as Chief Medical Officer
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appoin...
2024-09-03 15:20
